| |
|
Headlines:
|
 |
Back
to index
Hexamethylmelamine single agent
Abstract: Altretamine (hexamethylmelamine) in platinum-resistant and
platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II
trial.
OBJECTIVES: In an effort to critically examine the antitumor activity
of altretamine (hexamethylmelamine) as salvage therapy of platinum-refractory
ovarian cancer, the Gynecologic Oncology Group initiated a Phase II trial
of the agent administered in this clinical setting. METHODS: Altretamine
was administered at a dose of 260 mg/m2 orally for 14 days in a 28-day course.
Treatment was continued until disease progression or unacceptable side effects
prevented further therapy. A total of 36 patients (median age: 56.5) were
treated on this trial, of whom 33 were evaluable for toxicity and 30 for
response. All patients had previously received either cisplatin or carboplatin
and paclitaxel. RESULTS: The major side effect was emesis (grade 3-4, 7/33,
21%). The objective response rate was 10% (one complete response, two partial
responses). CONCLUSION: We conclude that altretamine has limited activity
in platinum-refractory ovarian cancer.
References
Markman M, Blessing JA, Moore D, Ball H, Lentz SS. Altretamine (hexamethylmelamine)
in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic
Oncology Group phase II trial. Gynecol Oncol 1998: 69:226 - 229.
|
|
|
|
Are you a doctor or a nurse?
Do you want to join the Doctors Lounge online medical community?
Participate in editorial activities (publish, peer review, edit) and
give a helping hand to the largest online community of patients.
Click on the link below to see the requirements:
Doctors Lounge Membership
Application |
|
| Regimen |
|
Hexamethylmelamine....... 260
mg / M2 / d PO days 1 - 14
FREQUENCY every 28 days |
|
|
| |
|
|
| |
Summary |
|
| |
Overall Response
Rate |
|
| |
Progression
Free Survival |
|
| |
Overall Survival |
|
| |
Toxicity |
|
| |
|
|
|
|
send
to a friend
printer
friendly version
